TRO19622 promotes myelin repair in a rat model of demyelination

References

• Rammohan KW. Axonal injury in multiple sclerosis. Curr Neurol Neurosci Rep 2003;3:231–7.
   PubMedGoogle Scholar
• Kuhlmann T, Lingfeld G, Bitsch A, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202–12.
   PubMed Web of Science ®Google Scholar
• Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001;81:871–927.
   PubMed Web of Science ®Google Scholar
• Menn B, Garcia-Verdugo JM, Yaschine C, Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 2006;26:7907–18.
   PubMed Web of Science ®Google Scholar
• Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol 2010;119:37–53.
   PubMed Web of Science ®Google Scholar
• Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002;3:705–14.
   PubMed Web of Science ®Google Scholar
• Zawadzka M, Franklin RJ. Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology. Curr Opin Neurol 2007;20:294–8.
   PubMed Web of Science ®Google Scholar
• Nait-Oumesmar B, Decker L, Lachapelle F, Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination. Eur J Neurosci 1999;11:4357–66.
   PubMed Web of Science ®Google Scholar
• Jablonska B, Aguirre A, Raymond M, Chordin-induced lineage plasticity of adult SVZ neuroblasts after demyelination. Nat Neurosci 2010;13:541–50.
   PubMedGoogle Scholar
• Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9:839–55.
   PubMed Web of Science ®Google Scholar
• Emery B. Regulation of oligodendrocyte differentiation and myelination. Science 2010;330:779–82.
   PubMed Web of Science ®Google Scholar
• Patrikios P, Stadelmann C, Kutzelnigg A, Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006;129:3165–72.
   PubMed Web of Science ®Google Scholar
• Murray PD, McGavern DB, Sathornsumetee S, Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain 2001;124:1403–16.
   PubMed Web of Science ®Google Scholar
• Kipp M, Clarner T, Dang J, The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009;118:723–36.
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Brunborg LA, Myhr KM, The cuprizone model for demyelination. Acta Neurol Scand Suppl 2008;188:72–6.
   PubMedGoogle Scholar
• Acs P, Kalman B. Pathogenesis of multiple sclerosis: what can we learn from the cuprizone model. Methods Mol Biol 2012;900:403–31.
   PubMedGoogle Scholar
• Wu QZ, Yang Q, Cate HS, MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model. J Magn Reson Imaging 2008;27:446–53.
   PubMedGoogle Scholar
• Zhang L, Yu W, Schroedter I, Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced MS mouse model. PLOS One 2012;7:e33901.
   PubMedGoogle Scholar
• Wang Y, Wang Q, Haldar JP, Quantification of increased cellularity during inflammatory demyelination. Brain 2011;134:3590–601.
   PubMedGoogle Scholar
• Chandran P, Upadhyay J, Markosyan S, Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 2012;202:446–53.
   PubMed Web of Science ®Google Scholar
• Yu O, Steibel J, Mauss Y, Remyelination assessment by MRI texture analysis in a cuprizone mouse model. Magn Reson Imaging 2004;22:1139–44.
   PubMedGoogle Scholar
• Magalon K, Zimmer C, Cayre M, Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol 2012;71:213–26.
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol JL, Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 2010;3:345–68.
   Google Scholar
• Bordet T, Buisson B, Michaud M, Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709–20.
   PubMed Web of Science ®Google Scholar
• Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13:568–80.
   PubMed Web of Science ®Google Scholar
• Clark SL, Ward JW. A variation of the Pal Weigert method for staining myelin sheaths. Stain Technology 1934;2:53–5.
   Google Scholar
• Vincze A, Mázló M, Seress L, A correlative light and electron microscopic study of postnatal myelination in the murine corpus callosum. Int J Dev Neurosci 2008;26:575–84.
   PubMed Web of Science ®Google Scholar
• Traboulsee AL, Li DK. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol 2006;98:125–46.
   PubMedGoogle Scholar
• Zhang J, Jones MV, McMahon MT, In vivo and ex vivo diffusion tensor imaging of cuprizone-induced demyelination in the mouse corpus callosum. Magn Reson Med 2012;67:750–9.
   PubMedGoogle Scholar
• Deloire MS, Ruet A, Hamel D, MRI predictors of cognitive outcome in early multiple sclerosis. Neurology 2011;76:1161–7.
   PubMed Web of Science ®Google Scholar
• Lee MA, Smith S, Palace J, Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging. Brain 1998;121:2095–102.
   PubMedGoogle Scholar
• Chandran P, Upadhyay J, Markosyan S, Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 2012;202:446–53.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Houdou S, Mito T, Development of myelination in the human fetal and infant cerebrum: a myelin basic protein immunohistochemical study. Brain Dev 1992; 14:1–6.
   PubMedGoogle Scholar
• Berger T, Rubner P, Schautzer F, Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139–45.
   PubMed Web of Science ®Google Scholar
• Tejada-Simon MV, Zang YC, Hong J, Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol 2003;53:189–97.
   PubMed Web of Science ®Google Scholar
• Kiernan JA. Histochemistry of staining methods for normal and degenerating myelin in the central and peripheral nervous systems. J Histotechnol 2007;30:87–106.
   Web of Science ®Google Scholar
• Bayliss HO. Lipid histochemistry (royal microscopical society: microscopy handbooks 06). Oxford: Oxford University Press; c1984, p46–8.
   Google Scholar
• Cook HC. Manual of histological demonstration techniques. London: Butterworths; c1974, p159–63.
   Google Scholar
• D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 2001;36:60–90.
   PubMed Web of Science ®Google Scholar
• Saab BJ, Saab AMP, Roder JC. Statistical and theoretical considerations for the platform re-location water maze. J Neurosci Meth 2011;198:44–52.
   PubMedGoogle Scholar
• Yang L, Guo YM, Han TZ, Age-specific impairment of morris water maze performance following neonatal exposure to magnetic resonance image in rats. Curr Neurovasc Res 2007;4:1–7.
   PubMedGoogle Scholar